Kim H, Suh K S, Jeon Y M, Park M S, Choi Y, Mori S, Hong G, Lee H W, Yi N J, Lee K W
Department of Surgery, Seoul National University College of Medicine, Chongno-gu, Seoul, Korea.
Transplant Proc. 2012 Apr;44(3):755-6. doi: 10.1016/j.transproceed.2012.01.066.
Thrombocytopenia (platelet < 60,000/mm(3)) and uncontrolled massive ascites (ascitic fluid > 1000 mL/d over 10 days) after liver transplantation (OLT), although uncommon, usually represent serious complications. Splenectomy is a useful treatment despite its many side effects. Recently, partial splenic artery embolization (PSAE) is considered to be a nonsurgical, less invasive treatment. In this study, we retrospectively reviewed the results of PSAE after OLT. Between October 2008 and February 2010, 11 patients underwent PSAE after OLT due to thrombocytopenia (n = 6) or refractory ascites (RA; n = 5). Six patients (54.5%) were males and 3 (27.3%) were children. The primary liver disease was virus-related liver cirrhosis (n = 6), biliary atresia (n = 3), fulminant hepatitis (n = 1), or alcoholic liver cirrhosis (n = 1). Seven grafts were from living and four from deceased donors. The major axial size of spleen was 12.1 to 23.4 cm and its average embolized volume, 76.4% (range = 70%-80%). As the result, the platelet count significantly increased after PSAE in all patients maintaining values greater than 100,000/mm(3) in four thrombocytopenic patients (66.7%). Cases of RA showed marked decreases after PSAE (100%). The follow-up was 6 to 28 months. After PSAE, patients experienced abdominal pain (n = 9, 81.8%), fever (n = 2, 18.2%), and abdominal distension (n = 2, 18.2%). However, there was no serious complication after PSAE such as splenic abscess, rupture, pancreatic infarction, sepsis, or death. In conclusion, PSAE was effective and safe and can be the choice for thrombocytopenia or RA related to hypersplenism after OLT.
肝移植(OLT)后出现血小板减少(血小板计数<60,000/mm³)和难以控制的大量腹水(10天内腹水>1000 mL/d),虽然不常见,但通常是严重的并发症。脾切除术虽有诸多副作用,但仍是一种有效的治疗方法。最近,部分脾动脉栓塞术(PSAE)被认为是一种非手术、侵入性较小的治疗方法。在本研究中,我们回顾性分析了OLT后PSAE的治疗结果。2008年10月至2010年2月,11例患者因血小板减少(n = 6)或难治性腹水(RA;n = 5)在OLT后接受了PSAE治疗。6例患者(54.5%)为男性,3例(27.3%)为儿童。原发性肝病为病毒相关性肝硬化(n = 6)、胆道闭锁(n = 3)、暴发性肝炎(n = 1)或酒精性肝硬化(n = 1)。7例移植物来自活体供者,4例来自已故供者。脾脏的主要轴向尺寸为12.1至23.4 cm,平均栓塞体积为76.4%(范围 = 70%-80%)。结果,所有患者在PSAE后血小板计数均显著增加,4例血小板减少患者(66.7%)的血小板计数维持在大于100,000/mm³的水平。RA患者在PSAE后腹水明显减少(100%)。随访时间为6至28个月。PSAE后,患者出现腹痛(n = 9,81.8%)、发热(n = 2,18.2%)和腹胀(n = 2,18.2%)。然而,PSAE后未出现诸如脾脓肿、破裂、胰腺梗死、败血症或死亡等严重并发症。总之,PSAE有效且安全,可作为OLT后与脾功能亢进相关的血小板减少或RA的治疗选择。